The mission of the Clinical Trials Support Resource is to serve the patients, faculty, and staff of the University of Texas M.D. Anderson Cancer Center by facilitating the approval and performance of clinical research of the highest quality in an ethical and cost-effective fashion. The Clinical Trials Support Resource is supported by the Office of Protocol Research (OPR) staff and is directed by the Associate Vice President for Clinical and Translational Research and an Administrative Director and is divided into four specialized areas: Protocol Approval and Regulatory Affairs, Office of Clinical Research Quality Assurance, Protocol Data Management System, and Research Finance. The Protocol Approval and Regulatory Affairs area supports the protocol approval process for the clinical Research Committee; the Psychosocial, Behavioral, and Health Services Research Committee; and the Surveillance Committee (Institutional Review Board) to ensure that scientific and patient protection issues are adequately addressed and that the protocols are approved at the institutional level before they are submitted to the NCI for approval. The Office of Clinical Research Quality Assurance monitors the quality of research data, serves as resource in improving data management, and provides an institutional mechanism for managing issues related to research deficiencies or problems. This office works closely with the Protocol Approval and Regulatory Affairs staff to ensure that the NCI stipulations are being met and that the requirement for the PRMS designation in protocol accrual is monitored is fulfilled. The Protocol Data Management System staff supports a comprehensive database developed for clinical research personnel at M.D. Anderson Cancer Center. It provides on-line patient registration for all clinical research protocols and is primarily responsible for tracking submission, patient accrual, adverse events, annual reviews, activations, and terminations for all clinical research protocols. It too plays a critical role in the PMRS process. The Research Finance staff is responsible for overseeing the protocol activity in the Clinical Research Unit and utilizing a cost model to prospectively project the cost and charge of protocols. Although each area is involved with special projects, the primary focus of the Clinical Trials Support Resource is to ensure that the principal investigators are in compliance with federal and institutional regulations, to maintain protocol-related information for the institution, to provide protocol management services to investigators, and to refine the financial system surrounding clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S1
Application #
6314535
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Boddu, Prajwal; Borthakur, Gautam; Koneru, Mythili et al. (2018) Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369
Takahashi, Nobuaki; Chen, Hsing-Yu; Harris, Isaac S et al. (2018) Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell 33:985-1003.e7
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76

Showing the most recent 10 out of 12418 publications